A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Tilapertin (Primary) ; Antipsychotics
  • Indications Schizophrenia
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms Study 165
  • Sponsors Amgen
  • Most Recent Events

    • 15 Jun 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 16 Jul 2012 Additional trial location (Czech Republic) addedd as reported by ClinicalTrials.gov.
    • 23 Jun 2012 Additional trial location identified as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top